MedPath

Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium

Conditions
Atrial Fibrillation
Registration Number
NCT03361202
Lead Sponsor
Institut Mutualiste Montsouris
Brief Summary

The aim of the study is to compare levels of differnts types of microparticles circulating before and after percutaneous occluding of the left atrium by patients with atrial fibrillation and patients control.

Hypothesis is that prothesis implantation will decrease levels of microparticles circulating in blood circulation because of occluding of the left atrium .

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria

atrial fibrillation group:

  • high embolic risk (CHADS-VASC2 score ≥4)
  • formal and final contraindication to anticoagulant therapy
  • no heart thrombus on ETO and TDM before percuraneous occluding

control group:

  • suspicion of stable coronary artery disease, coronary angiography scheduled and double platelet aggregation (clopidogrel and aspirine)
Exclusion Criteria

for both groups

  • congestive heart failure, severe aortic stenosis, EP or TVP early.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
levels of microparticles expressing phosphatidylserine in atrial fibrillation group45 days after Percutaneous Occluding of the Left Atrium.

blood samples analized by flow cytometry

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Institut Mutualiste Montsouris

🇫🇷

Paris, France

Institut Mutualiste Montsouris
🇫🇷Paris, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.